skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
Thought Leadership

As a supplement to our well-known quarterly outlook report, Key Potential Drug Launches in 2022 presents a long-term look at some key late-stage drugs projected to hit the market in 2022. These new drug launches represent new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.

In the Key Potential Drug Launches in 2022 report, you will find the following indications covered:

 

  • Allergy
    • Pruritus
  • Autoimmune/Immunology (A&I)
    • Crohn’s Disease
    • Myasthenia Gravis (MG)
    • Psoriasis
    • Ulcerative Colitis (UC)
  • Cardiovascular
    • Cardiomyopathy- Hypertrophic
    • Chronic Heart Failure – Preserved Ejection
    • Fraction (Chronic HFpEF)
  • Dermatology
    • Alopecia Areata
    • Burn Injury
    • Wrinkles
    • Vitiligo
  • Endocrine
    • Diabetes Mellitus, Type II
    • Menopause (including HRT)
    • Non-Alcoholic Steatohepatitis (NASH)
    • Osteoporosis/Osteopenia
  • Hematology
    • Hemophilia A and B
    • Thalassemia
  • Infectious Diseases (ID)
    • Clostridium Difficile-Associated-Diarrhea/Infection (CDAD/CDI)
    • Seasonal Influenza Vaccines
    • Cytomegalovirus (CMV) Infection
    • Fungal Infections- Non Systemic Dengue Fever
    • HIV/AIDS
    • HIV Prevention
  • Metabolic
    • Epidermolysis Bullosa
    • hATTR Amyloidosis with Polyneuropathy
    • Menkes Disease and TK2 Deficiency
    • Niemann-Pick Disease
    • Pyruvate Kinase Deficiency
    • Wilson’s Disease
  • Neurology
    • Fragile X Syndrome
    • Postsurgical Pain
    • Seizure Disorders (Epilepsy)
  • Obstetrics and Gynecology (Ob-Gyn)
    • Endometriosis
    • Uterine Fibroids
  • Oncology
    • Bone Marrow and Stem Cell Transplant
    • Cervical Cancer
    • Cervical Dysplasia
    • Chronic Lymphocytic Leukemia (CLL)
    • Chronic Myelogenous Leukemia (CML)
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Follicular Lymphoma (FL)
    • Gastric Cancer
    • Mantle Cell Lymphoma (MCL)
    • Marginal Zone Lymphoma (MZL)
    • Melanoma
    • Multiple Myeloma (MM)
    • Myelofibrosis (MF)
    • Myelodysplastic Syndrome (MDS)
    • Non-Small Cell Lung Cancer (NSCLC)
    • Ovarian Cancer
    • Peripheral T-Cell Lymphoma (PTCL)
    • Post-Transplant Lymphoproliferative Disease
    • Prostate Cancer
    • Uveal Melanoma
  • Ophthalmology
    • Wet AMD
  • Psychiatry
    • Bipolar Disorder
    • Schizophrenia
    • Major Depressive Disorder
  • Renal
    • Alport Syndrome
    • Focal Segmental
    • Glomerulosclerosis (FSGS)
    • Immunoglobulin A (IgA)
    • Nephropathy
  • Respiratory
    • Asthma


For more information on key drug launches and drug pipeline for 2022, please check-out Informa Pharma Intelligence’s industry news and insights with Scrip

Read also

  • Biomedtracker: see the drug development process through anal...

    2020 Deal-Making Roundup

    Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

    Topics Drug Review Coronavirus

  • Biomedtracker: see the drug development process through anal...

    Q3 2021 Outlook Report

    What major drug catalysts and events can you expect to see in the months ahead? Download your free extract from the Q3 2021 Outlook Report and infographic to find out. Shape your strategy with your inside look at what’s to come.

    Topics Drug Review

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    2021 Post-ASCO Insights and Analysis

    The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

    Topics Cancer

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: